Infusion of Anti-B7.1 (CD80) and Anti-B7.2 (CD86) Monoclonal Antibodies Inhibits Murine Graft-Versus-Host Disease Lethality in Part Via Direct Effects on CD4+ and CD8+ T Cells

Journal of Immunology

Volumn 157, Issue 8, 1996, Pages 3250-3259

  Blazar, Bruce R ^a,f   Sharpe, Arlene H ^c   Taylor, Patricia A ^a   Panoskaltsis Mortari, Angela ^a   Gray, Gary S ^d   Korngold, Robert ^e   Vallera, Daniel A ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d PFIZER INC   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CD86 PROTEIN, MOUSE; HLA ANTIGEN CLASS 2; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY;

ANIMAL; ARTICLE; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MOUSE; MOUSE MUTANT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY ANTIGENS CLASS II; INFUSIONS, INTRAVENOUS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MICE, SCID;

EID: 0030587828     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Vallera, D. A., and B. R. Blazar. 1989. T cell depletion for graft-versus-host-disease (GVHD) prophylaxis: a perspective on engraftment in mice and humans. Transplantation 47:751.
2. Bretscher, P., and M. Conn. 1970. A theory of self-nonself discrimination: paralysis and induction involve the recognition of one and two determinants on an antigen, respectively. Science 169:1042.
3. Jenkins, M. K., and R. H. Schwartz. 1987. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 165:302.
4. Schwartz, R. H. 1992. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71: 1065.
5. June, C. H., J. A. Bluestone, L. M. Nadler, and C. B. Thompson. 1994. The B7 and CD28 receptor families. Immunol. Today 15:321.
6. Freedman, A. S., G. J. Greeman, J. C. Horowitz, J. Daley, and L. M. Nadler. 1987. B7, a B cell restricted antigen which identifies pre-activated B cells. J. Immunol. 137:3260.
7. Freeman, G. J., A. S. Freedman, J. M. Segil, G. Lee, J. F. Whitman, and L. M. Nadler. 1989. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J. Immunol. 143:2714.
8. Freeman, G. J., J. G. Gribben, V. A. Boussiotis, J. Ng, V. Restivo, L. Lombard, G. S. Gray, and L. M. Nadler. 1993. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262:909.
9. Azuma, M., D. Ito, H. Yagita, K. Okumura, J. H. Phillips, L. Lanier, and C. Somoza. 1993. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366:76.
10. Clark, E. A., and J. A. Ledbetter. 1986. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc. Natl. Acad. Sci. USA 83:4494.
11. Armitage, R. J., W. C. Fanslow, L. Strockbine, R. A. Sato, K. N. Clifford, B. M. Macduff, D. M. Anderson, S. D. Gimpel, T. Davis-Smith, C. R. Maliszewski, E. A. Clark, C. A. Smith, K. H. Grabstein, K. Coman, and M. K. Spriggs. 1992. Molecular and biological characterization of a murine ligand for CD40. Nature 357:80.
12. Noelle, R. J., M. Roy, D. M. Shepard, I. Stamenkovi, J. A. Ledbetter, and A. Aruffo. 1992. A novel ligand on activated T helper cells binds CD40 and transduces the signal for cognate activation of B cells. Proc. Natl. Med. Sci. USA 89:6550.
13. Liu, Y., and C. A. Janeway, Jr. 1991. Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc. Natl. Acad. Sci. USA 89:3845.
14. Liu, Y., B. Jones, A. Aruffo, K. M. Sullivan, P. S. Linsley, C. A. Janeway, Jr. 1992. Heat-stable antigen is a costimulatory molecule for CD4 T cell growth. J. Exp. Med. 175:437.
15. Kwon, B. S. and S. M. Weissman. 1989. DNA sequences of two inducible T-cell genes. Proc. Natl. Acad. Sci. USA 86:1963.
16. Hurtado, J. C., S. H. Kim, K. E. Pollok, Z. H. Lee, and B. S. Kwon. 1995. Potential role of 4-1BB in T cell activation: comparison with the costimulatory molecule CD28. J. Immunol. 155:3360.
17. Linsley, P. S., W. Brady, M. Urnes, L. S. Grosmarie, J. A. Ledbetter, and N. K. Damle. 1991. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174:561.
18. Linsley, P. S., J. L. Greene, W. Brady, J. Bajorath, J. A. Ledbetter, R. Peach. 1994. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1:793.
19. Linsley, P. S., P. M. Wallace, J. Johnson, M. G. Gibson, J. L. Greene, J. A. Ledbetter, C. Singh, and M. A. Tepper. 1992. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257:792.
20. Lenschow, D. J., Y. Zeng, R. Thistlethwaite, A. Montag, W. Brady, M. G. Gibson, P. S. Linsley, and J. A. Bluestone. 1992. Long-term survival of xenogeneic pancreatic islet grafts by CTLA4-Ig. Science 257:789.
21. Turka, L. A., P. S. Linsley, H. Lin, W. Brady, J. M. Leiden, R. Q. Wei, M. L. Gibson, X. G. Zheng, S. Myrdal, D. Gordon, T. Bailey, S. F. Boling, and C. B. Thompson. 1992. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl. Acad. Sci. USA 89:11102.
22. Miller, S. D., C. L. Vanderlugt, D. J. Lenschow, J. G. Pope, N. J. Karandikar, M. C. Dalcanto, and J. A. Bluestone. 1995. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 3:739.
23. Lenschow, D. J., S. C. Ho, H. Sattar, L. Rhee, G. Gray, N. Nabavi, K. C. Herold, and J. A. Bluestone. 1995. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181:1145.
24. Blazar, B. R., P. A. Taylor, P. S. Linsley, and D. A. Vallera. 1994. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex (MHC) barrier in mice. Blood 83:3815.
25. Blazar, B. R., P. A. Taylor, A. Panoskaltsis-Mortari, G. S. Gray, and D. A. Vallera. 1995. Co-blockade of the LFA1: ICAM and CD28/B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully MHC disparate donor grafts. Blood 85:2607.
26. Blazar, B. R., P. A. Taylor, G. S. Gray, and D. A. Vallera. 1994. The Role of T Cell subsets in regulating the in vivo efficacy of CTLA4-Ig in preventing graft-versus-host disease in recipients of fully MHC or minor histocompatibility (miH) only disparate donor inocula. Transplantation 58:1422.
27. Kuchroo, V. K., M. P. Das, J. A. Brown, A. M. Tanger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease. Cell 80:707.
28. Freeman, G. J., V. A. Boussiotis, A. Anumanthan, G. M. Bernstein, X. Y. Ke, P D. Rennert, G. S. Gray, J. G. Gribben, and L. M. Nadler. 1995. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2:523.
29. Lanier, L. L., S. O'Fallon, C. Somoza, J. H. Phillips, P. S. Linsley, K. Okumura, D. Ito, and M. Azuma. 1995. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J. Immunol 154:97.
30. Wall, D. A., S. D. Hamberg, D. S. Reynolds, S. J. Burakoff, A. K. Abbas, and J. L. Ferrara. 1988. Immunodeficiency in graft-versus-host disease. I. Mechanism of immune suppression. J. Immunol. 140:2970.
31. Hoffman, R. A., J. M. Langrehr, S. M. Wren, K. E. Dull, S. T. Ildstad, S. A. McCarthy, and R. L. Simmons. 1993. Characterization of the immunosuppressive effects of nitric oxide in graft-versus-host disease. J. Immunol. 151:1508.
32. Sprent, J. and J. F. Miller. 1972. Thoracic duct lymphocytes from nude mice: migratory properties and life-span. Eur. J. Immunol. 2:384.
33. Sprent, J. and J. F. Miller. 1976. Effect of recent antigen priming on adoptive immune responses. III. Antigen-induced selective recruitment of subsets of recirculating lymphocytes reactive to H-2 determinants. J. Exp. Med 143:585.
34. Sprent, J., and H. von Boehmer. 1976. Activation of T lymphocytes to M locus determinants in vivo. I. Quantitation of T cell proliferation and migration into thoracic duct lymph. Eur. J. Immunol. 6:352.
35. Boussiotis, V. A., G. J. Freeman, J. G. Gribben, J. Daley, G. Gray, and L. M. Nadler. 1993. Activated human B lymphocytes express three CTLA-4 counter-receptors that costimulate T-cell activation. Proc. Natl. Acad. Sci. USA 90:11059.
36. Hatcock, K. S., G. Laszlo, C. Pucillo, P. Linsley, and R. J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180:631.
37. Lenschow, D. J., A. I. Sperling, M. P. Cooke, G. Freeman, L. Rhee, D. C. Decker, G. Gray, L. M. Nadler, C. C. Goodnow, and J. A. Bluestone. 1994. Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. J. Immunol. 153:1990.
38. Lenschow, D. J., G. H-T. Su, L. A. Zuckerman, N. Nabavi, C. L. Jellis, G. S. Gray, J. Miller, and J. A. Bluestone. 1993. Expression and functional significance of an additional ligand for CTLA-4. Proc. Natl. Acad. Sci. USA 90:11054.
39. Hathcock, K. S., G. Laszlo, C. Pucillo, P. Linsley, and R. J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180:631.
40. Azuma, M., H. Yssel, J. H. Phillips, H. Spits, and L. L. Lanier. 1993. Functional expression of B7/BB1 on activated T lymphocytes. J. Exp. Med. 177:845.
41. Prabhu Das, M. R., S. S. Zamvil, F. Borriello, H. L. Weiner, A. H. Sharpe, and V. K. Kuchroo. 1995. Reciprocal expression of co-stimulatory molecules, B7-1 and B7-2, on murine T cells following activation. Eur. J. Immunol. 25:207.
42. Hirokawa, M., A. Kitabayashi, J. Kuroki, and A. B. Miura. 1995. Signal transduction by B7/BB1 expressed on activated T lymphocytes- cross-linking of B7/ BB1 induces protein tyrosine phosphorylation and synergizes with signalling through T-cell receptor/CD3. Immunology 86:155.
43. Sansom, D. M., and N. D. Hall. 1993. B7/BB1, the ligand for CD28, is expressed on repeatedly activated human T cells in vitro. Eur. J. Immunol. 23:295.
44. Racke, M. K., D. E. Scott, L. Quigley, G. S. Gray, R. Abe, C. H. June, and P. J. Perrin. 1995. Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the inititation of experimental encephalomyelitis. J. Clin. Invest. 96:2195.
45. Freeman, G. J., F. Borriello, R. J. Hodes, H. Reiser, K. S. Hathcock, G. Laszlo, A. J. McKnight, J. Kim, L. Du, D. B. Lombard, G. S. Gray, L. M. Nadler, A. H. Sharpe. 1993. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 262:907.
46. + cells. J. Exp. Med. 180:307.
47. Korngold, R., and J. R. Bennink. 1984. Collection of mouse thoracic duct lymphocytes. Methods Enzymol. 108:270.
48. Razi-Wolf, Z., G. J. Freeman, F. Galvin, B. Benacerraf, L. Nadler, and H. Reiser. 1992. Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells. Proc. Natl. Acad. Sci USA 89: 4210.
49. Nabavi, N., G. J. Freeman, A. Gault, D. Godfrey, L. M. Nadler, and L. H. Glimcher. 1992. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature 360:266.
50. Chen, C., D. A. Faherty, A. Gault, S. E. Connaughton, G. D. Powers, D. I. Godfrey, and N. Nabavi. 1994. Monoclonal antibody 2D10 recognizes a novel T cell costimulatory molecule on activated murine B lymphocytes. J. Immunol. 152:2105.
51. Coulie, P. G., C. Uyttenhove, P. Wauters, N. Manolios, R. D. Klausner, L. E. Samelson, and J. Van Snick. 1991. Identification of a murine monoclonal antibody specific for an allotypic determinant on mouse CD3. Eur. J. Immunol. 21:1703.
52. Taswell, C. 1981. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J. Immunol. 126:1614.
53. Blazar, B. R., S. F. Carroll, and D. A. Vallera. 1991. Prevention of murine graft versus host disease and bone marrow alloengraftment across the MHC barrier following donor graft preincubation with anti-LFA1 immunotoxin. Blood 78: 3093.
54. Mantel, N. 1966. Evaluation of survival data in two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50:163.
55. + T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J. Immunol. 155:1032.
56. Hakim, F. T., R. Cepeda, G. S. Gray, C. H. June, and R. Abe. 1995. Acute graft-versus-host reaction can be aborted by blockade of costimulatory molecules. J. Immunol. 155:1757.
57. Fowler, D. H., K. Kurasawa, A. Husebekk, P. A. Cohen, and R. E. Gress. 1994. Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host disease reaction: regulation of cytokines and CD8+ lymphoid engraftment. J. Immunol. 152:1004.
58. + donor T cells fail to induce experimental acute graft-versus-host disease. J. Immunol. 155:585.
59. Piguet, P. F., G. E. Grau, B. Allet, and P. Vassalli. 1987. Tumor necrosis factor/ cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J. Exp. Med. 166:1280.
60. McCarthy, P. L., Jr., S. Abhyankar, S. Neben, G. Newman, C. Sieff, R. C. Thompson, S. J. Burakoff, and J. L. Ferrara. 1991. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 78: 1915.
61. Xun, C. Q., J. S. Thompson, C. D. Jennings, S. A. Brown, and M. B. Widmer. 1994. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 83:2360.
62. Vallera, D. A., P. A. Taylor, J. Vannice, A. Panoskaltsis-Mortari, and B. R. Blazar. 1995. Blocking of IL-1 and TNF in GVHD generated across minor or major histocompatibility barriers. Transplantation 60:1371.
63. DeSilva, D. R., K. B. Urdahl, and M. K. Jenkins. 1991. Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation. J. Immunol. 147:3261.
64. McArthur, J. G., and D. H. Raulet. 1993. CD28-induced costimulation of T helper type 2 cells mediated by induction of responsiveness to interleukin 4. J. Exp. Med. 178:1645.
65. + T cells to immobilized anti-TCR monoclonal antibody. J. Immunol. 152:1618.
66. 2 fragments prevent lethal murine graft-versus-host disease induced across the major histocompatibility barrier. J. Immunol. 150:265.
67. Gribben J. G., E. C. Guinan, V. A. Boussiotis, X.-Y. Ke, L. Linsley, C. Sieff, G. S. Gray, G. J. Freeman, and L. M. Nadler. 1996. Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Blood 87:4887.